M. Gao

发表

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, 2010, Nature.

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

M. Gao, R. Fridell, Chunfu Wang, 2011, Journal of Virology.

Characterizations of HCV NS5A replication complex inhibitors.

N. Meanwell, D. Langley, J. Lemm, 2013, Virology.

Anti-HCV drugs in the pipeline.

Qingsong Liu, Priscilla L. Yang, Kai Lin, 2011, Current opinion in virology.

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

A. Good, N. Meanwell, J. Lemm, 2013, Bioorganic & medicinal chemistry letters.

Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.

Carl T. Bergstrom, Chong-Hwan Chang, M. Witmer, 2011, Bioorganic & medicinal chemistry letters.

Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.

A. Mathur, J. Cutrone, N. Meanwell, 2017, Bioorganic & medicinal chemistry letters.

Ligand-induced changes in hepatitis C virus NS5B polymerase structure.

B. Beno, M. Gao, Min Ding, 2010, Antiviral research.

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

A. Lok, K. Reddy, P. Thuluvath, 2012 .

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

A. Lok, K. Reddy, T. Hassanein, 2014, The New England journal of medicine.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

L. Hamann, A. Fura, N. Meanwell, 2014, Journal of medicinal chemistry.

In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

Lingling Jia, M. Gao, R. Fridell, 2012, Antimicrobial Agents and Chemotherapy.

Replication-Competent Chimeric Hepatitis C Virus Subgenomic Replicons

J. Lemm, R. Colonno, M. Gao, 2005, Intervirology.

A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase.

M. Gao, S. Roberts, Karen L. Rigat, 2006, Analytical biochemistry.

Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNA

A. Lee, A. Lam, D. Gotchev, 2021, bioRxiv.

HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element

A. Lee, D. Gotchev, R. Rijnbrand, 2018, Antiviral research.

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.

N. Meanwell, J. Lemm, B. Pearce, 2014, Journal of medicinal chemistry.

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

P. Thuluvath, G. Everson, S. Pol, 2011 .

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

N. Meanwell, M. Deshpande, Scott W. Martin, 2011, ACS medicinal chemistry letters.

The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase.

M. Poss, M. Gao, R. Fridell, 2011, Organic & biomolecular chemistry.

Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon Assay

J. Lemm, R. Colonno, M. Gao, 2005, Antimicrobial Agents and Chemotherapy.

Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

B. Kienzle, Lingling Jia, M. Gao, 2014, Antimicrobial Agents and Chemotherapy.

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Chong-Hwan Chang, M. Witmer, B. Beno, 2014, Journal of medicinal chemistry.

Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.

B. Beno, M. Poss, J. Lemm, 2012, Bioorganic & medicinal chemistry letters.

HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

A. Good, N. Meanwell, J. Lemm, 2013, Bioorganic & medicinal chemistry letters.

Herpes Simplex Virus DNA Cleavage and Packaging Proteins Associate with the Procapsid prior to Its Maturation

W. Newcomb, S. Weller, M. Gao, 2001, Journal of Virology.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

A. Good, N. Meanwell, J. Lemm, 2014, Journal of medicinal chemistry.

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

Min Gao, M. Gao, R. Fridell, 2010, Antimicrobial Agents and Chemotherapy.

Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

B. Beno, J. Marcinkeviciene, L. Abell, 2014, The Journal of Biological Chemistry.

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

N. Meanwell, J. Lemm, R. Colonno, 2014, Antimicrobial Agents and Chemotherapy.

Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

P. Tebas, J. Lemm, D. Grasela, 2014, Antimicrobial Agents and Chemotherapy.

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

J. Lemm, M. Gao, Mengping Liu, 2012, Antimicrobial Agents and Chemotherapy.

Effect on HCV Replication by Combinations of Direct Acting Antivirals 5 Including NS 5 A Inhibitor Daclatasvir 6 7 8

J. Lemm, M. Gao, Mengping Liu, 2012 .

RNA template-mediated inhibition of hepatitis C virus RNA-dependent RNA polymerase activity.

M. Gao, Jin‐Hua Sun, S. Roberts, 2008, Archives of biochemistry and biophysics.

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Min Gao, Anna Persson, D. Grasela, 2011, Hepatology.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations

Xin Huang, Min Gao, Susan Roberts, 2011, Hepatology.

Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

M. Gao, R. Fridell, Jin‐Hua Sun, 2013, Antimicrobial Agents and Chemotherapy.

Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Min Gao, M. Gao, 2013, Current opinion in virology.

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052

R. Nettles, M. Gao, R. Fridell, 2012, Hepatology.

The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth

W. Newcomb, J. Brown, S. F. Ditusa, 1994, Journal of virology.

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

M. Imamura, N. Hiraga, K. Chayama, 2013, Gut.

Functional conservations of the alkaline nuclease of herpes simplex type 1 and human cytomegalovirus.

W. Newcomb, J. Brown, S. Weller, 1998, Virology.

The C-terminal third of UL42, a HSV-1 DNA replication protein, is dispensable for viral growth.

S. F. Ditusa, M. Cordingley, M. Gao, 1993, Virology.

Evidence for Controlled Incorporation of Herpes Simplex Virus Type 1 UL26 Protease into Capsids

W. Newcomb, S. Weller, M. Gao, 2000, Journal of Virology.

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Qi Gao, Min Gao, Steven Sheriff, 2017, Journal of medicinal chemistry.

Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase.

N. Meanwell, J. Lemm, J. Kadow, 2016, Bioorganic & medicinal chemistry letters.

Potency and Resistance Analysis of Hepatitis C Virus NS5B Polymerase Inhibitor BMS-791325 on All Major Genotypes

J. Lemm, M. Gao, Mengping Liu, 2014, Antimicrobial Agents and Chemotherapy.

Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

Lingling Jia, M. Gao, R. Fridell, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A

Lingling Jia, M. Gao, R. Fridell, 2011, Antimicrobial Agents and Chemotherapy.

Identification of Hepatitis C Virus NS5A Inhibitors

N. Meanwell, M. Deshpande, Scott W. Martin, 2009, Journal of Virology.

The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA

Fei Liu, R. Rijnbrand, M. Sofia, 2020, Antimicrobial Agents and Chemotherapy.

Intragenic Complementation of Hepatitis C Virus NS5A RNA Replication-Defective Alleles

M. Gao, R. Fridell, Dike Qiu, 2012, Journal of Virology.

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

L. Hamann, N. Meanwell, J. Lemm, 2011, The Journal of general virology.

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

A. Lok, K. Reddy, T. Hassanein, 2013 .

Specific Inhibition of Bovine Viral Diarrhea Virus Replicase

J. Lemm, R. Colonno, M. Gao, 2003, Journal of Virology.

SAR studies on a series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides: potent inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.

B. Beno, M. Poss, J. Lemm, 2011, Bioorganic & medicinal chemistry letters.

Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.

M. Witmer, B. Beno, K. Kish, 2011, Bioorganic & medicinal chemistry letters.

HCV NS5A replication complex inhibitors.

M. Gao, D. O’Boyle, S. Roberts, 2016, Current opinion in pharmacology.

Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids

W. Newcomb, J. Brown, R. Colonno, 1996, Journal of virology.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

Min Gao, Nicholas A. Meanwell, Yong Tu, 2015, Nature.

HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.

N. Meanwell, J. Lemm, M. Gao, 2012, Bioorganic & medicinal chemistry letters.

Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus

W. Newcomb, J. Brown, M. Gao, 1994, Journal of virology.

Na, an autoproteolytic product of the herpes simplex virus type 1 protease, can functionally substitute for the assembly protein ICP35

V. Preston, M. Gao, B. Robertson, 1997, Journal of virology.

Release of the catalytic domain N(o) from the herpes simplex virus type 1 protease is required for viral growth

W. Newcomb, J. Brown, M. Gao, 1995, Journal of virology.

The synthesis and evaluation of a novel class of (E)-3-(1-cyclohexyl-1H-pyrazol-3-yl)-2-methylacrylic acid hepatitis C virus polymerase NS5B inhibitors.

Carl T. Bergstrom, B. Beno, Scott W. Martin, 2011, Bioorganic & medicinal chemistry letters.

Synergistic Activity of Combined NS5A Inhibitors

N. Meanwell, M. Cockett, M. Gao, 2015, Antimicrobial Agents and Chemotherapy.

Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures

N. Meanwell, Scott W. Martin, Joseph L. Cantone, 2011, Antimicrobial Agents and Chemotherapy.

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

D. Grasela, A. Persson, T. Marbury, 2011, Hepatology.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

N. Meanwell, D. Langley, J. Lemm, 2015, Nature.

63 CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052

M. Gao, R. Fridell, F. Mcphee, 2011 .